1
2
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New Engl J Med 2016, 375
(18), 1738-1748.
3
4
5
12. Munster, P. N.; Hamilton, E. P.; Estevez, L. G.; De Boer, R. H.; Mayer, I. A.; Campone, M.; Asano,
S.; Bhansali, S.; Zhang, V.; Hewes, B.; Juric, D. Ph IB study of LEE011 and BYL719 in combination
with letrozole in ER+, Her2-breast cancer. J Clin Oncol 2014, 32 (26).
6
7
8
13. Munster, P. N.; Hamilton, E. P.; Franklin, C.; Bhansali, S.; Wan, K.; Hewes, B.; Juric, D. Phase lb
study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive,
HER2-negative breast cancer (ER+, HER2-BC). J Clin Oncol 2014, 32 (15).
9
14. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nature reviews. Cancer
2008, 8 (8), 592-603.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
15. Zhang, J.; Jiang, X.; Jiang, Y.; Guo, M.; Zhang, S.; Li, J.; He, J.; Liu, J.; Wang, J.; Ouyang, L.
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer
drugs. European journal of medicinal chemistry 2016, 108, 495-504.
16. An, X. D.; Liu, H.; Xu, Z. L.; Jin, Y.; Peng, X.; Yao, Y. M.; Geng, M.; Long, Y. Q. Discovery of
potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural
optimization. Bioorg Med Chem Lett 2015, 25 (3), 708-16.
17. You, W. K.; Sennino, B.; Williamson, C. W.; Falcon, B.; Hashizume, H.; Yao, L. C.; Aftab, D. T.;
McDonald, D. M. VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet
Cancer. Cancer research 2011, 71 (14), 4758-4768.
18. Kurzrock, R.; Sherman, S. I.; Ball, D. W.; Forastiere, A. A.; Cohen, R. B.; Mehra, R.; Pfister, D.
G.; Cohen, E. E. W.; Janisch, L.; Nauling, F.; Hong, D. S.; Ng, C. S.; Ye, L.; Gagel, R. F.; Frye, J.;
Muller, T.; Ratain, M. J.; Salgia, R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase
Inhibitor, in Patients With Medullary Thyroid Cancer. J Clin Oncol 2011, 29 (19), 2660-2666.
19. Zhan, Z. S.; Ai, J.; Liu, Q. F.; Ji, Y. C.; Chen, T. T.; Xu, Y. C.; Geng, M. Y.; Duan, W. H.
Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and
Cellular Activity. ACS medicinal chemistry letters 2014, 5 (6), 673-678.
20. McConville, M.; Bradley, D. F.; Zhou, K.; Schiffrin, D. J.; O'Neil, I. A. Selective trioxolane based
bifunctional molecular linkers for covalent heme surface functionalisation. Chem Commun 2014, 50 (2),
186-188.
21. Le Brazidec, J. Y.; Pasis, A.; Tam, B.; Boykin, C.; Wang, D.; Marcotte, D. J.; Claassen, G.; Chong,
J. H.; Chao, J.; Fan, J.; Nguyen, K.; Silvian, L.; Ling, L.; Zhang, L.; Choi, M.; Teng, M.; Pathan, N.;
Zhao,
S.;
Li,
T.;
Taveras,
A.
Structure-based
design
of
2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors. Bioorg Med Chem Lett
2012, 22 (12), 4033-7.
22. Shao, H.; Shi, S.; Huang, S.; Hole, A. J.; Abbas, A. Y.; Baumli, S.; Liu, X.; Lam, F.; Foley, D. W.;
Fischer, P. M.; Noble, M.; Endicott, J. A.; Pepper, C.; Wang, S. Substituted
4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray
crystal structures, structure-activity relationship, and anticancer activities. J Med Chem 2013, 56 (3),
640-59.
40
41